Tag results
Trials tagged with: "after 2 prior treatments"
Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma after at least 2 prior treatment regimens
Browse by popular tags
abvd act acute lymphoblastic leukaemia acute myelogenous leukemia (aml) acute myeloid leukaemia ade admire adoptive cellular therapy after 2 prior treatments alemtuzumab all allogeneic allogeneic stem cell transplant aml aml 17 angioimmunoblastic lymphoma antiviral therapy arctic autologous stem cell transplant autologous transplant autologus stem cell transplant azacitidine b-cell b-cell chronic lymphocytic leukaemia bevacizumab bexarotene blood cancers blood transfusions bone marrow
NHS Logo
The Clinical research facility is part of the NIHR and is funded by the Department of Health
Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma after at least 2 prior treatment regimens